190 related articles for article (PubMed ID: 33310889)
21. The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma.
Gu J; Song S; Han H; Xu H; Fan G; Qian C; Qiu Y; Zhou W; Zhuang W; Li B
Mol Pharm; 2018 Nov; 15(11):5387-5396. PubMed ID: 30339013
[TBL] [Abstract][Full Text] [Related]
22. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
[TBL] [Abstract][Full Text] [Related]
24. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
25. Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.
Shi J; Song S; Han H; Xu H; Huang M; Qian C; Zhang X; Ouyang L; Hong Y; Zhuang W; Li B
Mol Pharm; 2018 Sep; 15(9):4139-4147. PubMed ID: 30048594
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
27. BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells.
Camero S; Camicia L; Marampon F; Ceccarelli S; Shukla R; Mannarino O; Pizer B; Schiavetti A; Pizzuti A; Tombolini V; Marchese C; Dominici C; Megiorni F
Cancer Lett; 2020 Jun; 479():71-88. PubMed ID: 32200036
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine.
Tian CQ; Chen L; Chen HD; Huan XJ; Hu JP; Shen JK; Xiong B; Wang YQ; Miao ZH
Cell Death Dis; 2019 Jul; 10(8):557. PubMed ID: 31324754
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
30. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.
Astorgues-Xerri L; Vázquez R; Odore E; Rezai K; Kahatt C; Mackenzie S; Bekradda M; Coudé MM; Dombret H; Gardin C; Lokiec F; Raymond E; Noel K; Cvitkovic E; Herait P; Bertoni F; Riveiro ME
Leuk Lymphoma; 2019 Dec; 60(12):3067-3070. PubMed ID: 31204545
[No Abstract] [Full Text] [Related]
31. Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
Mensah AA; Cascione L; Gaudio E; Tarantelli C; Bomben R; Bernasconi E; Zito D; Lampis A; Hahne JC; Rinaldi A; Stathis A; Zucca E; Kwee I; Gattei V; Valeri N; Riveiro ME; Bertoni F
Haematologica; 2018 Dec; 103(12):2049-2058. PubMed ID: 30076183
[TBL] [Abstract][Full Text] [Related]
32. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
Healy JR; Hart LS; Shazad AL; Gagliardi ME; Tsang M; Elias J; Ruden J; Farrel A; Rokita JL; Li Y; Wyce A; Barbash O; Batra V; Samanta M; Maris JM; Schnepp RW
Pediatr Blood Cancer; 2020 Jun; 67(6):e28267. PubMed ID: 32307821
[TBL] [Abstract][Full Text] [Related]
33. A monocyte-keratinocyte-derived co-culture assay accurately identifies efficacies of BET inhibitors as therapeutic candidates for psoriasiform dermatitis.
Wu X; Shi Z; Hsu DK; Chong J; Huynh M; Mendoza L; Yamada D; Hwang ST
J Dermatol Sci; 2020 Oct; 100(1):31-38. PubMed ID: 32900573
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 8-Methyl-pyrrolo[1,2-
Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
[TBL] [Abstract][Full Text] [Related]
35. The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma.
Yu B; Liu L; Cai F; Peng Y; Tang X; Zeng D; Li T; Zhang F; Liang Y; Yuan X; Li J; Dai Z; Liao Q; Lv XB
Cancer Cell Int; 2022 Feb; 22(1):64. PubMed ID: 35135529
[TBL] [Abstract][Full Text] [Related]
36. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Berthon C; Raffoux E; Thomas X; Vey N; Gomez-Roca C; Yee K; Taussig DC; Rezai K; Roumier C; Herait P; Kahatt C; Quesnel B; Michallet M; Recher C; Lokiec F; Preudhomme C; Dombret H
Lancet Haematol; 2016 Apr; 3(4):e186-95. PubMed ID: 27063977
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
[TBL] [Abstract][Full Text] [Related]
40. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]